Dry Eye Disease Market Size, Epidemiology, Treatment Trends, and Forecast to 2035

The dry eye disease market size reached a value of USD 3.3 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 5.4 billion by 2035, exhibiting a growth rate (CAGR) of 4.64% during 2025-2035.

The dry eye disease market in 2025 is witnessing steady expansion, fueled by rising awareness, a growing number of diagnosed cases, and consistent advances in treatment technology. Dry eye disease, also known as keratoconjunctivitis sicca, is a common condition that occurs when the eyes do not produce enough tears or when the tears evaporate too quickly. This leads to inflammation, discomfort, and potential damage to the surface of the eye.

Request for a sample of this report: https://www.imarcgroup.com/dry-eye-disease-market/requestsample

The rising prevalence of dry eye disease is a major factor enabling market growth. This condition affects millions of people worldwide and is more common among the elderly, post-menopausal women, contact lens wearers, and heavy computer users. The increase in pollution, low humidity, and the use of central heating also exacerbate the condition. In 2025, the number of patients able to recognize symptoms and access screening tools is rising and therefore seeking medical attention increases.

The market for dry eye diseases encompasses a vast array of products, including: artificial tears, anti-inflammatory eye drops, punctal plugs, and in-office procedures. Although most patients are initially treated with over-the-counter artificial tears, an increasing number of patients experiencing more moderate to severe forms of the disease now require some form of prescription therapy. With an increasing patient population, pharmaceutical companies are now focusing on treating both the underlying symptoms and inflammation with next-generation therapies.

Targeted biologics along with other novel anti-inflammatory drugs are becoming increasingly popular in the treatment of dry eye syndrome. Medications which target certain inflammatory pathways like lifitegrast, as well as her ceptin and cyclosporin-based therapies, are on the rise. Other avenues where researchers are investing their focus include regenerative medicine and gene therapy which could potentially alleviate the chronic symptoms for an extended period of time.

Improvements in technology are having a major impact on the development of the market. The use of devices which provide thermal pulsation therapy, intense pulsed light (IPL) and meibomian gland expression eye surgery are on the rise in ophthalmology clinics. These procedures, which treat the oil gland dysfunction, tackle the underlying factors of evaporative dry eye syndrome and enhance the stability of the tear film.

Tools like mobile apps and home diagnostic kits help the patients in tracking their symptoms and following prescribed treatment plans with greater accuracy. Screening tools powered with AI and teleophthalmology platforms broaden the scope of care delivery, particularly in remote and neglected areas.

Buy Full Report @ https://www.imarcgroup.com/checkout?id=22249&method=809

The more popular angle of preservative-free and natural products for eye care is another noteworthy development. More patients are considering the consequences of using strong chemicals in eye drops and are driving manufacturers to develop milder, more natural formulations.

With growing awareness and evolving technology, the market for dry eye disease in 2025 anticipates further expansion. Healthcare professionals are now more adequately trained for the diagnosis and management of the condition, and patients have access to an increasingly comprehensive range of effective and easy-to-use treatment options. The evolution of the dry eye disease market is centered on ongoing technological advancements, customization, and enhanced quality of life for patients around the globe.

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

According to the report, the United States has the largest patient pool for dry eye disease and also represents the largest market for its treatment.

Competitive Landscape

Bausch + Lomb
Viatris
Alcon
HanAll BioPharma
Oculis
Stuart Therapeutics
Okyo Pharma

IMARC Group Offers Other Reports:

Heart Failure Market https://www.openpr.com/news/4017314/how-the-heart-failure-market-is-growing-in-2025-what-new

Lambert-Eaton Myasthenic Syndrome Market https://www.openpr.com/news/4017563/how-the-lambert-eaton-myasthenic-syndrome-market-is-growing

Ophthalmoplegia Market https://www.openpr.com/news/4018000/how-the-ophthalmoplegia-market-is-growing-in-2025-what-s-new

Acne Vulgaris Market https://www.openpr.com/news/4027432/acne-vulgaris-market-across-7-key-regions-projected-to-hit-usd

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.